Tobramycin magnesium stearate microparticles for inhalation, compositions thereof, and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-10857169-B2
Application number	US-96730610-A
Country	US
Kind code	B2
Filing date	Dec 14, 2010
Priority date	Dec 14, 2009
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

Powder formulations for inhalation which comprise microparticles containing an antibiotic and magnesium stearate are useful for the treatment of bacterial infections associated with certain pulmonary diseases.

First claim

The invention claimed is:

1. A capsule for use with a dry powder inhaler, which contains a dry powder formulation for delivery of tobramycin to the lungs, said formulation consisting of mechano-fused microparticles,
wherein said mechano-fused microparticles consist of:
(a) particles of tobramycin in an amount of 99 to 99.5% w/w; and
(b) magnesium stearate in an amount of 0.5 to 1% w/w,
wherein magnesium stearate coats at least 50% of the surface of the particles of tobramycin,
wherein said microparticles have an amount of residual water lower than 0.5% w/w,
wherein said capsule contains 12 to 40 mg of said tobramycin expressed as free base, and
wherein administration of said formulation from said capsule to the lungs of a subject results in rapid delivery of said tobramycin and local absorption of said tobramycin by said lungs of said subject.

2. A method for preparing a capsule according to claim 1 , comprising:
i) feeding particles of tobramycin and magnesium stearate particles into a driven vessel of a Mechano-Fusion apparatus;
ii) processing said particles of tobramycin and magnesium stearate particles for a time of at least 2 minutes, to obtain microparticles;
iii) collecting said microparticles; and
iv) filling said microparticles into a capsule.

3. A method according to claim 2 , wherein said processing is conducted for at least 5 minutes.

4. A method for the treatment of a Pseudomonas aeruginosa infection associated with cystic fibrosis, comprising administering an effective amount of tobramycin from a capsule according to claim 1 to a subject in need thereof,
wherein administration of said formulation from said capsule to the lungs of a subject results in rapid delivery of said tobramycin and local absorption of said tobramycin by said lungs of said subject.

5. A capsule according to claim 1 , which contains 15 to 30 mg of said tobramycin expressed as free base.

6. A capsule according to claim 1 , which contains 15 mg of said tobramycin expressed as free base.

7. A capsule according to claim 1 , wherein said capsule is a 3 HPMC capsule or a gelatine capsule.

8. A capsule according to claim 1 , wherein said capsule is a 3 HPMC capsule.

9. A capsule according to claim 1 , wherein said capsule is a gelatine capsule.

10. A capsule according to claim 1 , wherein said mechano-fused microparticles consist of:
(a) particles of tobramycin in an amount of 99.5% w/w; and
(b) magnesium stearate in an amount of 0.5% w/w.

Assignees

• Morton David
• Zhou Qi
• Musa Rossella
• Chiesi Farm Spa

Inventors

• Morton David
• Zhou Qi
• Musa Rossella

Classifications

• A61K31/7036 Primary

  having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins · CPC title

• A61K9/5015

  Organic compounds, e.g. fats, sugars · CPC title

• A61K9/5089

  Processes · CPC title

• A61K9/0075

  for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title

• A61K9/145

  with organic compounds · CPC title